Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 3/20 | 0.39 |
| ▸ | ESRRB | O95718 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12721376 | 1.00 | CTSS (0.43) | CTSSCTSKMIFKDM4EF13A1 | |
| SCHEMBL12721396 | 0.89 | NPC1 (0.44) | GAACA12CA1CA7CA14 | |
| SCHEMBL13614219 | 0.87 | CA12 (0.51) | CTSSCTSKCA12CA1CA7 | |
| SCHEMBL4297214 | 0.84 | KDM4E (0.42) | KDM4EF13A1ESRRGESRRBCA2 | |
| SCHEMBL4297210 | 0.84 | KDM4E (0.42) | KDM4EF13A1ESRRGESRRBCA2 | |
| SCHEMBL4817662 | 0.82 | FFAR1 (0.50) | KDM4E | |
| SCHEMBL3742023 | 0.82 | ALDH1A1 (0.46) | GAACA12CA1CA7CA14 | |
| SCHEMBL13628910 | 0.82 | S1PR1 (0.50) | KDM4ECA12CA1CA2 | |
| SCHEMBL10476123 | 0.82 | ALDH1A1 (0.46) | GAACA12CA1CA7CA14 | |
| SCHEMBL1626585 | 0.81 | ADRB3 (0.38) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622866-B1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2012-07-25 | — | — | EP | disclosed |
| US-7928093-B2 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7928093-B2 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7928093-B2 | Amino-propanol derivatives | NOVARTIS AG (CH) | 2011-04-19 | — | — | US | disclosed |
| US-7825260-B2 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7728020-B2 | Amino acid derivatives | NOVARTIS AG (CH) | 2010-06-01 | — | — | US | disclosed |
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-7612238-B2 | Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| EP-1753712-B1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1753712-B1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1725519-A1 | AMINO ACID DERIVATIVES | Novartis AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | NOVARTIS AG (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1622866-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1377593-B1 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005118523-A1 | AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005085179-A1 | AMINO ACID DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2004096757-A1 | AMINOPROPANOL DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040147490-A1 | 2-Amino-propanol derivatives | ALBERT RAINER (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1377593-A2 | 2-AMINO-PROPANOL DERIVATIVES | Novartis AG (CH) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002076995-A2 | 2-AMINO-PROPANOL DERIVATIVES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211656-A1 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators | S1PR1, S1PR3, S1PR2 | CTSS 4365/4885CTSK 4384/4885MIF 4557/4885 |
| US-20040147490-A1 | 2-Amino-propanol derivatives | CD4, HLA-DRB1, CCR1 | CTSS 4737/4885CTSK 4553/4885MIF 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.